The Society Pages
The Leukemia & Lymphoma
Society Commits $40.3
Million to New Cancer
Research
More than 75 scientific researchers at
leading academic and medical institutions around the world received new
research funding from The Leukemia
& Lymphoma Society (LLS) to address
critical unmet medical needs for blood
cancer patients. The following is a selection of award recipients.
Acute Myeloid Leukemia
LLS awarded a series of grants focused
on acute myeloid leukemia (AML).
• Katharine Hsu, MD, PhD, Memorial
Sloan Kettering Cancer Center, was
awarded a Career Development
Program (CDP) grant to study
how to eradicate AML in human
leukocyte antigen-matched
allogeneic hematopoietic cell
transplantation by harnessing
donor natural killer cell activity.
• Anas Younes, MD, Memorial
Sloan Kettering Cancer Center, will
study novel immune therapy of
lymphoma.
Translational Research Program
The Translational Research Program
(TRP) grants fund new and innovative
research that shows promise of moving
from laboratory discoveries to clinical
application. This year, 29 researchers
received a TRP grant, including:
• Charles Mullighan, MBBS, MSc,
MD, St. Jude Children’s Research
Hospital, will study therapeutic
targeting of acute erythroid
leukemia.
• Ulrich Steidl, MD, PhD, Albert
Einstein College of Medicine, will
study mechanisms of initiation and
therapeutic targeting of PU.1 lowinduced AML.
• Ann Leen, PhD, Baylor College of
Medicine, was awarded a Rising
Tide Foundation for Clinical Cancer
Research (RTFCCR)/LLS grant to
test multi-tumor antigen-targeted
T-cell therapy for AML.
• Madhav Dhodapkar, MB, BS,
Yale University, will study
targeting antigenic substrates
in monoclonal gammopathy and
potentially progression to multiple
myeloma.
• Iannis Aifantis, PhD, New York
University School of Medicine, was
awarded a Translational Research
Program (TRP) grant to test
targeting the tumor-suppressive
functions of the cohesin complex
in AML.
• Jianhua Yu, PhD, The Ohio State
University, will study CS1 chime